Sector News

Regeneron chief nabs $42M, but he’ll have to pay his own club fees this year

March 23, 2015
Life sciences
Regeneron chief Len Schleifer has topped the ranks of biopharma’s highest-paid skippers for the past couple of years now, and though his salary may be rising still, being CEO doesn’t quite come with all the perks it used to.
 
According to the company’s recent proxy filing, Regeneron’s compensation committee nixed Schleifer’s automobile allowance, as well as his club membership dues and annual credit card membership fees. And money he got to pay taxes on legal, tax and financial planning advisers? That’s gone too.
 
Don’t worry about Schleifer, though. He’ll still get plenty of benefits, including life insurance, long-term disability, and medical malpractice insurance, Regeneron’s proxy says–and that’s all on top of his salary, bonus and option awards.
 
Speaking of that combo, it reached $41.86 million last year without the added perks, putting Schleifer’s total 2014 compensation at $41.97 million. That haul built on the $36.27 million paycheck he nabbed in 2013 and the $30.05 million he netted in 2012, both of which topped the industry’s “highest-paid” CEO lists in their respective years.
 
Schleifer has hard-charging eye drug Eylea to thank for those hefty sums–and for Regeneron’s recent success. The med stormed out of the gate after hitting the U.S. market back in late 2011, and since then, it’s trounced forecast after forecast and racked up a host of indications on both sides of the pond. Plus, the company has a PCSK9 cholesterol drug, alirocumab, waiting for FDA approval. Analysts figure Regeneron and partner Sanofi can pump that med to blockbuster sales, too.
 
And for that, he’s not the only Regeneron exec raking in the big bucks. The company’s R&D chief, George Yancopoulos, famously scored a record-setting $81 million pay package back in 2012 after developing Eylea–and while that package shrank last year, he still took home $31 million to lead the R&D executive pay field.
 
Like Schleifer, though, Yancopoulos is kissing some of his freebies goodbye this year; his automobile allowance is gone, too, and the credit card membership fees will now be his to pay.
 
By Carly Helfand
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach